{"id":362,"date":"2020-11-30T12:38:08","date_gmt":"2020-11-30T20:38:08","guid":{"rendered":"https:\/\/cloudbreakpharma.com\/?p=362"},"modified":"2021-03-04T14:36:01","modified_gmt":"2021-03-04T22:36:01","slug":"cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006","status":"publish","type":"post","link":"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/","title":{"rendered":"Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-006"},"content":{"rendered":"<p><strong>Irvine, CA \u2013 November 30, 2020<\/strong> \u2013 Cloudbreak Therapeutics, a clinical-stage company focused on developing innovative therapies for diseases and conditions of the eye, had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 study using Investigational New Drug (IND) CBT-006 to treat Meibomian Gland Dysfunction Associated Dry Eye Disease.<\/p>\n<p>The Phase 2 clinical trial is a U.S.-based, randomized, double-masked, multi-center trial evaluating the safety, tolerability and efficacy of 2.5% and 10% CBT-006 in comparison of vehicle when instilled three times a day (TID) dosing for 3 months in patients with MGD-DED.<\/p>","protected":false},"excerpt":{"rendered":"<p>Irvine, CA \u2013 November 30, 2020 \u2013 Cloudbreak Therapeutics, a clinical-stage company focused on developing innovative therapies for diseases and conditions of the eye, had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 study using Investigational New Drug (IND) CBT-006 to treat Meibomian Gland Dysfunction Associated Dry [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":363,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-362","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-006 - Cloudbreak Pharma, Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-006 - Cloudbreak Pharma, Inc.\" \/>\n<meta property=\"og:description\" content=\"Irvine, CA \u2013 November 30, 2020 \u2013 Cloudbreak Therapeutics, a clinical-stage company focused on developing innovative therapies for diseases and conditions of the eye, had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 study using Investigational New Drug (IND) CBT-006 to treat Meibomian Gland Dysfunction Associated Dry [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/\" \/>\n<meta property=\"og:site_name\" content=\"Cloudbreak Pharma, Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-30T20:38:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-04T22:36:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2021\/02\/iStock-1022809006-min.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2537\" \/>\n\t<meta property=\"og:image:height\" content=\"1182\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Cloudbreak Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Cloudbreak Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\\\/\"},\"author\":{\"name\":\"Cloudbreak Therapeutics\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/person\\\/4ce5c35f55e45013fcc3b72d09b3c5ef\"},\"headline\":\"Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-006\",\"datePublished\":\"2020-11-30T20:38:08+00:00\",\"dateModified\":\"2021-03-04T22:36:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\\\/\"},\"wordCount\":112,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/02\\\/iStock-1022809006-min.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"zh-CN\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\\\/\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\\\/\",\"name\":\"Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-006 - Cloudbreak Pharma, Inc.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/02\\\/iStock-1022809006-min.jpg\",\"datePublished\":\"2020-11-30T20:38:08+00:00\",\"dateModified\":\"2021-03-04T22:36:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\\\/#breadcrumb\"},\"inLanguage\":\"zh-CN\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/02\\\/iStock-1022809006-min.jpg\",\"contentUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/02\\\/iStock-1022809006-min.jpg\",\"width\":2537,\"height\":1182},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-006\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\",\"name\":\"Cloudbreak Pharma, Inc.\",\"description\":\"Seeing Life Better Through Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cloudbreakpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-CN\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\",\"name\":\"Cloudbreak Pharma, Inc.\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/cloudbreak-logo.svg\",\"contentUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/cloudbreak-logo.svg\",\"width\":824,\"height\":199,\"caption\":\"Cloudbreak Pharma, Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/person\\\/4ce5c35f55e45013fcc3b72d09b3c5ef\",\"name\":\"Cloudbreak Therapeutics\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ef9bec0ab272fc95323871422822e118291f7a174570d6c0068d381a87f998dd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ef9bec0ab272fc95323871422822e118291f7a174570d6c0068d381a87f998dd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ef9bec0ab272fc95323871422822e118291f7a174570d6c0068d381a87f998dd?s=96&d=mm&r=g\",\"caption\":\"Cloudbreak Therapeutics\"},\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/zh\\\/author\\\/infocloudbreaktherapeutics-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-006 - Cloudbreak Pharma, Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/","og_locale":"zh_CN","og_type":"article","og_title":"Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-006 - Cloudbreak Pharma, Inc.","og_description":"Irvine, CA \u2013 November 30, 2020 \u2013 Cloudbreak Therapeutics, a clinical-stage company focused on developing innovative therapies for diseases and conditions of the eye, had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 study using Investigational New Drug (IND) CBT-006 to treat Meibomian Gland Dysfunction Associated Dry [&hellip;]","og_url":"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/","og_site_name":"Cloudbreak Pharma, Inc.","article_published_time":"2020-11-30T20:38:08+00:00","article_modified_time":"2021-03-04T22:36:01+00:00","og_image":[{"width":2537,"height":1182,"url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2021\/02\/iStock-1022809006-min.jpg","type":"image\/jpeg"}],"author":"Cloudbreak Therapeutics","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005":"Cloudbreak Therapeutics","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/#article","isPartOf":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/"},"author":{"name":"Cloudbreak Therapeutics","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/person\/4ce5c35f55e45013fcc3b72d09b3c5ef"},"headline":"Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-006","datePublished":"2020-11-30T20:38:08+00:00","dateModified":"2021-03-04T22:36:01+00:00","mainEntityOfPage":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/"},"wordCount":112,"commentCount":0,"publisher":{"@id":"https:\/\/cloudbreakpharma.com\/#organization"},"image":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/#primaryimage"},"thumbnailUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2021\/02\/iStock-1022809006-min.jpg","articleSection":["News"],"inLanguage":"zh-CN"},{"@type":"WebPage","@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/","url":"https:\/\/cloudbreakpharma.com\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/","name":"Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-006 - Cloudbreak Pharma, Inc.","isPartOf":{"@id":"https:\/\/cloudbreakpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/#primaryimage"},"image":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/#primaryimage"},"thumbnailUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2021\/02\/iStock-1022809006-min.jpg","datePublished":"2020-11-30T20:38:08+00:00","dateModified":"2021-03-04T22:36:01+00:00","breadcrumb":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/#breadcrumb"},"inLanguage":"zh-CN","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cloudbreakpharma.com\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/"]}]},{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/#primaryimage","url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2021\/02\/iStock-1022809006-min.jpg","contentUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2021\/02\/iStock-1022809006-min.jpg","width":2537,"height":1182},{"@type":"BreadcrumbList","@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-006\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cloudbreakpharma.com\/"},{"@type":"ListItem","position":2,"name":"Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-006"}]},{"@type":"WebSite","@id":"https:\/\/cloudbreakpharma.com\/#website","url":"https:\/\/cloudbreakpharma.com\/","name":"Cloudbreak Pharma, Inc.","description":"\u533b\u836f\u4f7f\u6211\u4eec\u80fd\u66f4\u597d\u7684\u89c6\u89c9\u4eab\u53d7\u751f\u6d3b","publisher":{"@id":"https:\/\/cloudbreakpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cloudbreakpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-CN"},{"@type":"Organization","@id":"https:\/\/cloudbreakpharma.com\/#organization","name":"Cloudbreak Pharma, Inc.","url":"https:\/\/cloudbreakpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/logo\/image\/","url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2022\/08\/cloudbreak-logo.svg","contentUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2022\/08\/cloudbreak-logo.svg","width":824,"height":199,"caption":"Cloudbreak Pharma, Inc."},"image":{"@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/person\/4ce5c35f55e45013fcc3b72d09b3c5ef","name":"Cloudbreak Therapeutics","image":{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/secure.gravatar.com\/avatar\/ef9bec0ab272fc95323871422822e118291f7a174570d6c0068d381a87f998dd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ef9bec0ab272fc95323871422822e118291f7a174570d6c0068d381a87f998dd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ef9bec0ab272fc95323871422822e118291f7a174570d6c0068d381a87f998dd?s=96&d=mm&r=g","caption":"Cloudbreak Therapeutics"},"url":"https:\/\/cloudbreakpharma.com\/zh\/author\/infocloudbreaktherapeutics-com\/"}]}},"_links":{"self":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/comments?post=362"}],"version-history":[{"count":0,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/362\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media\/363"}],"wp:attachment":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media?parent=362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/categories?post=362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/tags?post=362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}